Other safety alerts
|
| |
| DH receives notification from MSD regarding the discontinuation in local supply of "Gardasil Vaccine Inj (pre-filled syringe)" (HK-54935), a 4-valent Human Papilloma Virus (HPV) vaccine, by the end of 2018 |
| |
On 12 September 2018, Merck Sharp & Dohme (Asia) Ltd (MSD) notified the Department of Health about the discontinuation in local supply of a 4-valent Human Papilloma Virus (HPV) vaccine, namely "Gardasil Vaccine Inj (pre-filled syringe)" (HK-54935), by the end of 2018 because its local demand has been reduced significantly.
According to MSD, letters have been issued today (13 September 2018) to the customers notifying them about this planned discontinuation of supply of the HPV vaccine. MSD also informed that another 4-valent HPV "Gardasil Vaccine Inj (vial)" (HK-54934) has not been supplied in Hong Kong for at least 2 years.
At present, there are three types of HPV vaccines registered in Hong Kong, including "Cervarix" (HK-56180) (i.e. bivalent HPV vaccine) registered by GlaxoSmithKline Limited (GSK); "Gardasil" (i.e. 4-valent HPV vaccine) [presented in two injectable forms (HK-54934 and HK-54935)]; and "Gardasil-9" (HK-64239) (i.e. 9-valent HPV vaccine) both registered by MSD. They are all prescription medicines.
DH will maintain close liaison with the HPV vaccines suppliers to monitor their supply situation. Members of public should contact their healthcare professionals for seeking appropriate advice and vaccination recommendation if and when necessary.
Ends/Thursday, Sep 13, 2018
Issued at HKT 15:30
|
| |
